Cognition Therapeutics, Inc. CGTX PHARMA
Company Overview
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is zervimesine, an orally delivered small molecule to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, which is in Phase 2 clinical studies for the treatment of Alzheimer's disease and Mild Cognitive Impairment, as well as geographic atrophy secondary to dry age-related macular degeneration and dementia with Lewy bodies. Cognition Therapeutics, Inc. was incorporated in 2007 and is based in Purchase, New York.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -17.21% |
| 6 Months: | -6.48% |
| 3 Months: | -16.53% |
| 1 Month: | -6.48% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)48.09 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 68.2% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | CGTX Cognition Therapeutics, Inc. PHARMA | 1.01 | -5.94 | $96.04M | 0.00% | -138.68% | -83.76% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income | - | - | -4.46M | -5.58M | -5.98M | -5.22M | -9.41M | -12.21M | -12.62M | -8.97M | -11.82M | -14.74M | -14.10M | -14.68M | -14.46M | -13.78M | -13.98M | -6.38M | -8.82M | -7.74M |
| Net Income | -2.51M | -1.67M | -1.79M | 223.00K | -1.49M | -3.11M | -3.84M | -5.75M | -6.62M | -6.17M | -4.73M | -6.75M | -9.15M | -7.04M | -9.94M | -8.48M | -6.73M | -4.93M | -4.57M | -3.93M |
| Diluted EPS | - | - | -5.31 | -1.64 | -4.77 | -8.12 | -0.17 | -0.25 | -0.29 | -0.21 | -0.16 | -0.22 | -0.27 | -0.18 | -0.25 | -0.14 | -0.11 | -0.06 | -0.05 | -0.04 |
| R&D Expense | - | - | 3.40M | 4.43M | 4.89M | 3.67M | 6.52M | 9.10M | 8.27M | 5.43M | 8.50M | 11.67M | 10.55M | 11.58M | 11.39M | 10.79M | 11.48M | 3.77M | 6.12M | 5.10M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Income | -17.41M | -28.60M | -43.55M | -50.72M | -53.97M | -47.80M |
| Net Income | -7.84M | -11.72M | -21.40M | -25.79M | -33.97M | -23.49M |
| Diluted EPS | -23.76 | -3.13 | -0.91 | -0.86 | -0.86 | -0.32 |
| R&D Expense | 12.89M | 18.57M | 30.32M | 37.20M | 41.68M | 37.19M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 7.12M | 59.14M | 50.42M | 35.16M | 30.23M | 48.39M |
| Total Equity | -58.42M | -68.18M | 51.27M | 40.25M | 24.47M | 18.75M | 34.27M |
| Cash & Equivalents | - | 5.19M | 54.72M | 41.56M | 29.92M | 25.01M | 36.81M |
| Total Liabilities | - | 19.93M | 7.86M | 10.18M | 10.69M | 11.48M | 14.12M |
| Current Liabilities | - | 3.25M | 7.86M | 7.79M | 10.17M | 11.14M | 13.92M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -3.43M | - | -18.53M | -16.02M | -28.47M | -24.59M |
| Investing Cash Flow | -10.00K | - | -171.00K | -147.00K | -4.00K | 9.00K |
| Financing Cash Flow | 5.76M | - | 5.55M | 4.52M | 23.57M | 36.57M |
| Capital Expenditure | -10.00K | -27.00K | -171.00K | -147.00K | -4.00K | - |
| Free Cash Flow | -3.44M | - | -18.70M | -16.16M | -28.48M | -24.59M |
| Net Change in Cash | - | - | -13.16M | -11.64M | -4.91M | 11.99M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - |
| ROE % | 11.5% | -22.9% | -53.2% | -105.4% | -181.2% | -68.5% |
| ROCE % | -449.9% | -55.8% | -102.2% | -202.9% | -282.7% | -138.7% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Bios Capital Management, LP | 6.31% | 6.00M | $6.24M |
| 2 | Davenport & Co LLC | 4.48% | 4.26M | $4.43M |
| 3 | Vanguard Capital Management LLC | 3.62% | 3.44M | $3.58M |
| 4 | Blackrock Inc. | 1.33% | 1.26M | $1.31M |
| 5 | Chescapmanager LLC | 1.05% | 997.03K | $1.04M |
| 6 | Geode Capital Management, LLC | 0.96% | 910.01K | $946.41K |
| 7 | Renaissance Technologies, LLC | 0.73% | 693.29K | $721.02K |
| 8 | Hilton Capital Management, LLC. | 0.58% | 548.95K | $570.91K |
| 9 | Vanguard Fiduciary Trust Co | 0.53% | 508.22K | $528.55K |
| 10 | CM Management, LLC | 0.47% | 450.00K | $468.00K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CGTX
An Alzheimer's drug will be discussed Sept. 15 by Cognition Therapeutics - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiswFBVV95cUxNQllOU2tOZnJDV1ZtU1ZQbm1QVUVTdXB1NFp4RU00LTJBYmYzb2pHOHduNVJUNDZVWVI1TjZMQ1JyV0l2NXVVeXRDek1WdmljeGRiT193R0FzQjZ3NU1iOG5zc05kOTRIZTVzYUhpNHFtMDIyWmpJRHplWEQ1Tnc0dVdYcWFWUTNOa2Frem…
We're Keeping An Eye On Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Rate - Moomoo
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxQbGJyTUFKYVRlZUE2TGlLbUlwRm14Z1BhbEVHMnZJeW9yWVZNSWVGVWNtZTRzTlBjOHZkclZPZEhVM2JnUEJXZ19kZUl2VlJRZnJwWklvOW9vcmFYUGc0WkdlUlJfWk5KTVpMS2c3RDVNdzR3N1ZmV19zZUNvYWtwQ0lxS0QxU2NhcmZ0dT…
Is Cognition Therapeutics, Inc. (CGTX) Moving Closer to a Registrational Trial in Dementia With Lewy Bodies? - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxQdUtBcS1YV25LcVhTTGh3SG5KVWRvTE9HZDVYNzZjcWsyLXVrd0h3b21NNy1xNlhMX19wdDJGYmtJUUdFMTNBSFlqMTg4eEhSN0lPWHZrWXFNMl9oOC1LR25vZFZhRi15WldPZGtxQUFfM056YWk0Tk93UDNsbzlMNVEzTHZDWDVHLW5nM3…
CGTX Forecast — Price Target — Prediction for 2027 - tradingview.com
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE9LNGx3MS1kRmtabWhON0ZqTzg3ZHBWNTdocTdYb2NacHdhQW5PakVDeU1KcnJXNmdLRDdxa241WHdtTmlSY1VpTV9iNWJCZE82WXBJeElkeUJaWFZ6ZHVHemRzdFpfZWtTcmFqMy1OTFYxVnlXTjltNjFn?oc=5" target="_blank">CGT…
$CGTX stock is up 11% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxPczJ5bFpZREMwSG55TGtEdWlzVHNMd0doVTNXaDE3MHdKbmVVVFRoV1NBLTQyempVTy14dnpZVUFFRlRlNzMwVERBZzJFa3NhVlU3dUYxdXVJNGdCMjhlU2lqRlU2LTItYWNDa1phZHN6c1dCMFZ5UFRCUFhxNGFlN2YyQ1JFZnJULW5wb3…
CGTX - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE5PUlQ5OXNudFBfZFY0dm5NUG1Ram9HdmMyS1RYOThjTEhGclpXeGpObmxfYUVBVHFKU0ZHWXU4bGdvQ0g0ekE?oc=5" target="_blank">CGTX</a> <font color="#6f6f6f">Finviz</font>…
CGTX — Frequently Asked Questions
What is the current share price of Cognition Therapeutics, Inc. (CGTX)?
As of 2026-09-19 21:16 PDT, Cognition Therapeutics, Inc. (CGTX) trades at $1.01 on NasdaqCM. Its 52-week range is $0.60 to $3.18.
What is the market capitalisation of CGTX?
Cognition Therapeutics, Inc. (CGTX) has a market capitalisation of $96.04M on NasdaqCM.
What is the P/E ratio of CGTX?
CGTX trades at a trailing price-to-earnings (P/E) ratio of -5.94. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 2.85.
What is the return on equity (ROE) of CGTX?
CGTX has a return on equity (ROE) of -83.76%. Its return on capital employed (ROCE) is -138.68%.
Is CGTX a good stock to buy?
This page provides a data-driven analysis of Cognition Therapeutics, Inc. (CGTX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.